Anheart Therapeutics Inc
AnHeart Therapeutics is a clinical-stage biopharmaceutical company based in New York, NY, dedicated to developing innovative precision therapies for individuals with cancer. Their pipeline includes promising clinical stage assets such as Taletrectinib, a ROS1 inhibitor for non-small cell lung cancer, Safusidenib, an mIDH1 inhibitor for glioma and other tumors, and AB-329, an axl inhibitor for overcoming checkpoint inhibitor resistance in various tumors.
With a mission to advance precision oncology therapeutics, AnHeart Therapeutics collaborates with leading organizations like Innovent and Foundation Medicine to develop companion diagnostics and gain regulatory approvals for their novel therapies. Their commitment to scientific excellence and strategic partnerships positions them at the forefront of the fight against cancer.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.
